



**TTK Healthcare
LIMITED**

TTKHC:SEC:SL:012:26

January 22, 2026

**BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001**

**National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051**

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Outcome of the Board Meeting - Disclosure under Regulation 30 of SEBI (LODR)
Regulations, 2015**

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, we provide below the outcome of the meeting of the Board of Directors held today (i.e.) **January 22, 2026:**

1. Unaudited Financial Results along with Limited Review Report for the Third Quarter and Period Ended December 31, 2025:

The Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Third Quarter and Period Ended December 31, 2025, duly reviewed by the Audit Committee at their meeting held earlier today and approved by the Board of Directors in their meeting, are attached herewith as **Annexure–A.**

2. Reconstitution of the various Committees of the Board, w.e.f. February 03, 2026:

Consequent to conclusion of the second and final term of appointment of Mr N Ramesh Rajan as Independent Director of the Company on February 02, 2026, the various Committees of the Board have been reconstituted, w.e.f. February 03, 2026, as detailed below:

(a) Audit Committee

Name of the Director	Category	Position
Mr V Ranganathan	Independent Director	Chairman
Mr K Shankaran	Non-Independent Director	Member
Mrs Subashree Anantkrishnan	Independent Director	Member
Mr V Sundaresan	Additional Independent Director	Member

..... 2



**TTK Healthcare
LIMITED**

2

(b) Nomination and Remuneration Committee

Name of the Director	Category	Position
Mr Murali Neelakantan	Independent Director	Chairman
Mr K Shankaran	Non-Independent Director	Member
Mrs Hastha Shivaramakrishnan	Independent Director	Member
Mrs Subashree Anantkrishnan	Independent Director	Member
Mr V Sundaresan	Additional Independent Director	Member

(c) Risk Management Committee

Name of the Director	Category	Position
Mrs. Hastha Shivaramakrishnan	Independent Director	Chairman
Mr. K Shankaran	Non-Independent Director	Member
Mr V Sundaresan	Additional Independent Director	Member
Mr. S Kalyanaraman	Managing Director & CEO	Member
Mr. B V K Durga Prasad	President – Finance (CFO)	Member
Mr. V K Srinivasan	Sr. Vice President – Finance	Member
Mr B Harikumar	Assistant Vice President – IT	Member

3. Amendments to the Policy on Related Party Transactions, in line with the SEBI (LODR) (Fifth Amendment) Regulations, 2025 dated November 18, 2025 notified on November 19, 2025:

The Policy on Related Party Transactions (“Policy”) was amended in line with the SEBI (LODR) (Fifth Amendment) Regulations, 2025 dated November 18, 2025 notified on November 19, 2025.

The said amended policy was duly considered, approved and adopted by the Audit Committee and the Board of Directors at their respective meetings held today and was also made available on the website of the Company at www.ttkhealthcare.com.

This intimation is also made available on the website of the Company at www.ttkhealthcare.com.

The Board Meeting commenced at 12 noon and concluded at 1.00 p.m.

Kindly take the above information / documents on record.

Thanking you

Yours faithfully

For TTK Healthcare Limited

(GOWRY A JAISHANKAR)

DGM – Legal & Company Secretary

Encl.: a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED DECEMBER 31, 2025

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

		(Rs. in lakhs)					
Sl. No.	Particulars	For the Quarter ended			For the Period ended		For the Year ended
		(31/12/2025)	(30/09/2025)	(31/12/2024)	(31/12/2025)	(31/12/2024)	(31/03/2025)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	20,929.89	20,356.77	20,474.48	63,929.64	61,113.38	80,149.34
II.	Other Income	1,743.34	1,901.29	1,783.69	5,438.19	5,256.62	7,125.49
III.	Total Income (I + II)	22,673.23	22,258.06	22,258.17	69,367.83	66,370.00	87,274.83
IV.	Expenses:						
	(a) Cost of materials consumed	5,138.18	4,804.82	4,665.89	14,899.72	14,576.01	19,533.81
	(b) Purchase of Stock-in-trade	5,395.58	4,877.38	4,432.13	14,975.70	13,883.75	18,694.85
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(772.24)	102.88	705.05	(146.96)	(318.62)	(1,337.02)
	(d) Employee benefits expense	4,172.86	4,110.82	3,842.63	12,416.76	11,450.81	15,090.96
	(e) Finance Costs	68.32	83.84	82.33	229.12	241.95	332.42
	(f) Depreciation and Amortization Expense	222.15	221.18	211.08	662.14	616.68	833.37
	(g) Other Expenses	6,281.80	5,927.45	6,059.71	20,269.73	19,238.89	24,683.92
	Total Expenses (IV)	20,506.65	20,128.37	19,998.82	63,306.21	59,689.47	77,832.31
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	2,166.58	2,129.69	2,259.35	6,061.62	6,680.53	9,442.52
VI.	Exceptional Items [Refer Note No.3 below]	(757.87)	-	-	(757.87)	1,977.05	1,390.66
VII.	Profit / (Loss) before Tax (V + VI)	1,408.71	2,129.69	2,259.35	5,303.75	8,657.58	10,833.18
VIII.	Tax Expense:						
	(1) Current Tax	440.00	535.00	585.00	1,440.00	2,115.00	2,655.00
	(2) Deferred Tax	(84.55)	17.57	1.11	(66.57)	(8.28)	12.49
	(3) Tax relating to earlier years [Refer Note No.4 below]	0.00	(461.52)	-	(461.52)	-	-
IX.	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	1,053.26	2,038.64	1,673.24	4,391.84	6,550.86	8,165.69
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expense from Discontinued Operations	-	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	1,053.26	2,038.64	1,673.24	4,391.84	6,550.86	8,165.69
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	(36.08)	20.94	(115.27)	44.31	255.55	(402.94)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.36	(0.73)	17.24	(1.63)	(32.72)	63.21
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	1,018.54	2,058.85	1,575.21	4,434.52	6,773.69	7,825.96
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)	-	-	-	-	-	1,04,650.36
XVI.	Earnings per Equity Share (For Continuing Operations):						
	(1) Basic (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79
	(2) Diluted (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79
XVII.	Earnings per Equity Share (For Discontinued Operations):						
	(1) Basic (in Rs.)	-	-	-	-	-	-
	(2) Diluted (in Rs.)	-	-	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):						
	(1) Basic (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79
	(2) Diluted (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79



Notes:

- (1) The above financial results for the Third Quarter and Period ended December 31, 2025 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 22, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) (a) During the First Quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
(b) During the Fourth Quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
(c) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information presently available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company has assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, has presented the same as Exceptional items in the Statement of Profit and Loss for the period ended December 31, 2025. The incremental impact comprises of Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which a provision of Rs.350 lakhs created in the Fourth Quarter of FY 2020-21 has been adjusted, resulting in a net charge of Rs.757.87 lakhs recognised in the Current Quarter. The Company is also evaluating other potential impacts of the Labour Codes, including those relating to the contract workforce; however, in the absence of final Central and State Rules and further regulatory clarifications, such impacts cannot be reasonably estimated at this stage and their quantum and materiality remain indeterminate.
- (4) The tax relating to earlier years represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments.
- (5) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on December 31, 2025.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) This statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : January 22, 2026



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED DECEMBER 31, 2025

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Period ended		For the Year ended
		(31/12/2025)	(30/09/2025)	(31/12/2024)	(31/12/2025)	(31/12/2024)	(31/03/2025)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
	(a) Animal Welfare	3,791.21	3,547.42	3,281.91	10,527.02	9,576.95	12,637.05
	(b) Consumer Products	5,541.05	5,627.18	5,936.72	18,731.27	19,201.67	24,492.52
	(c) Medical Devices	2,554.14	2,557.00	2,144.79	7,997.94	6,754.87	9,014.53
	(d) Protective Devices	5,398.58	4,882.52	5,936.82	15,552.34	15,904.27	20,663.87
	(e) Foods	3,633.80	3,732.57	3,167.66	11,090.70	9,652.03	13,305.98
	(f) Others	11.11	10.08	6.58	30.37	23.59	35.39
	Total	20,929.89	20,356.77	20,474.48	63,929.64	61,113.38	80,149.34
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	20,929.89	20,356.77	20,474.48	63,929.64	61,113.38	80,149.34
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
	(a) Animal Welfare	395.54	316.92	297.54	946.59	778.15	1,098.52
	(b) Consumer Products	225.18	955.48	645.08	1,306.37	2,059.89	2,345.32
	(c) Medical Devices	492.50	605.67	525.39	1,904.98	1,572.40	2,215.05
	(d) Protective Devices	(110.23)	(1,024.84)	(31.10)	(1,679.41)	(379.14)	252.62
	(e) Foods	339.78	380.16	143.12	1,014.05	316.93	449.89
	(f) Others	12.69	10.74	8.06	31.25	24.60	14.70
	Total	1,355.46	1,244.13	1,588.09	3,523.83	4,372.83	6,376.10
	Less : Finance Cost	68.32	83.84	82.33	229.12	241.95	332.42
	Less : Unallocable Expenses (Net of Unallocable Income)	(121.57)	(969.40)	(753.59)	(2,009.04)	(4,526.70)	(4,789.50)
	Total Profit (+) / Loss (-) before tax	1,408.71	2,129.69	2,259.35	5,303.75	8,657.58	10,833.18
		As on 31/12/2025	As on 30/09/2025	As on 31/12/2024	As on 31/12/2025	As on 31/12/2024	As on 31/03/2025
3.	Segment Assets:						
	(a) Animal Welfare	4,659.50	4,430.45	4,004.22	4,659.50	4,004.22	3,859.37
	(b) Consumer Products	4,198.40	4,625.21	4,002.19	4,198.40	4,002.19	4,521.96
	(c) Medical Devices	8,413.59	8,518.98	6,857.97	8,413.59	6,857.97	7,135.97
	(d) Protective Devices	13,136.93	12,703.20	13,468.01	13,136.93	13,468.01	13,715.76
	(e) Foods	6,000.53	5,986.79	6,724.78	6,000.53	6,724.78	6,931.64
	(f) Others	295.57	291.91	296.75	295.57	296.75	289.73
	Total	36,704.52	36,556.54	35,353.92	36,704.52	35,353.92	36,454.43
	Unallocated	94,560.51	92,998.20	91,296.94	94,560.51	91,296.94	91,664.24
	Total Assets	1,31,265.03	1,29,554.74	1,26,650.86	1,31,265.03	1,26,650.86	1,28,118.67
4.	Segment Liabilities:						
	(a) Animal Welfare	3,112.05	2,960.84	3,144.78	3,112.05	3,144.78	2,920.65
	(b) Consumer Products	4,847.86	5,056.74	6,186.62	4,847.86	6,186.62	6,568.01
	(c) Medical Devices	1,623.81	1,857.67	1,592.10	1,623.81	1,592.10	1,367.74
	(d) Protective Devices	3,672.34	3,891.30	4,476.14	3,672.34	4,476.14	4,324.52
	(e) Foods	1,659.86	1,502.84	1,525.38	1,659.86	1,525.38	1,665.60
	(f) Others	133.47	134.88	148.60	133.47	148.60	136.92
	Total	15,049.39	15,404.27	17,073.62	15,049.39	17,073.62	16,983.44
	Unallocated	6,689.34	5,642.70	4,124.70	6,689.34	4,124.70	4,630.41
	Total Liabilities	21,738.73	21,046.97	21,198.32	21,738.73	21,198.32	21,613.85



Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segmentwise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
Executive Chairman

Place : Chennai
Date : January 22, 2026



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
 CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED DECEMBER 31, 2025

Sl. No.	Particulars	For the Quarter ended			For the Period ended		(Rs. in lakhs)
		(31/12/2025)	(30/09/2025)	(31/12/2024)	(31/12/2025)	(31/12/2024)	For the Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total income from Operations	20,929.89	20,356.77	20,474.48	63,929.64	61,113.38	80,149.34
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	2,166.58	2,129.69	2,259.35	6,061.62	6,680.53	9,442.52
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	1,408.71	2,129.69	2,259.35	5,303.75	8,657.58	10,833.18
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	1,053.26	2,038.64	1,673.24	4,391.84	6,550.86	8,165.69
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,018.54	2,058.85	1,575.21	4,434.52	6,773.69	7,825.96
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	1,04,650.36
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
(a)	Basic (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79
(b)	Diluted (in Rs.)	7.45	14.43	11.84	31.08	46.36	57.79

Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and period ended December 31, 2025, in respect of TTK Healthcare Limited (the Company) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Third Quarter and period ended December 31, 2025 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) The above financial results for the Third Quarter and period ended December 31, 2025 in respect of the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its respective meetings held on January 22, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (4) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (5) (a) During the First Quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
 (b) During the Fourth Quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
 (c) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information presently available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company has assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, has presented the same as Exceptional items in the Statement of Profit and Loss for the period ended December 31, 2025. The incremental impact comprises of Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which a provision of Rs.350 lakhs created in the Fourth Quarter of FY 2020-21 has been adjusted, resulting in a net charge of Rs.757.87 lakhs recognised in the Current Quarter. The Company is also evaluating other potential impacts of the Labour Codes, including those relating to the contract workforce; however, in the absence of final Central and State Rules and further regulatory clarifications, such impacts cannot be reasonably estimated at this stage and their quantum and materiality remain indeterminate.
- (6) The tax relating to earlier years represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments.
- (7) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on December 31, 2025.
- (8) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive ChairmanPlace : Chennai
Date : January 22, 2026

Independent Auditor's Review Report on review of Interim Financial Results

To the Board of Directors of TTK Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **TTK Healthcare Limited** (the "Company"), for the quarter and period ended 31st December 2025 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") which has been initialed by us for identification.

Management's Responsibility

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

3. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Obligations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018

P. Devi

Devi P

Partner

Membership No. 223137



Place: Chennai

Date: 22nd January 2026

UDIN: *26223137LJNAJP8793*